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Table 1
Prevalence of the Three BRCA1 and BRCA2 Founder Mutations in Ashkenazi Jewish Women Who Have Never Had a Diagnosis of Breast
or Ovarian Cancer, as a Function of Family History of Breast Cancer and Age at Testing (Hartge et al. [1999], table 3)
AGE AT TESTING (YEARS)
PROPORTION (%) OF INDIVIDUALS WITH BRCA1/BRCA2 FOUNDER MUTATIONS WHEN
No. of First-Degree Relatives with Breast Cancer Is Early Diagnosis in Affected Relatives Is
0 1 2 Not Present Present
!40 9/566 (1.6) 10/123 (8.1) 0/1 (0) 5/62 (8.1) 5/62 (8.1)
40–49 14/888 (1.6) 9/217 (4.1) 0/7 (0) 3/143 (2.1) 6/81 (7.4)
50–59 8/636 (1.3) 4/163 (2.5) 2/12 (17) 4/119 (3.4) 2/56 (3.6)
60 4/615 (.7) 1/163 (.6) 1/28 (3.6) 1/124 (.8) 1/67 (1.5)
Total 35/2,705 (1.3) 24/666 (3.6) 3/48 (6.3) 13/448 (2.9) 14/266 (5.3)
Am. J. Hum. Genet. 65:1771, 1999
Modeling the Probability That Ashkenazi Jewish
Women Carry a Founder Mutation in BRCA1 or
BRCA2
To the Editor:
The Washington study (see Struewing et al. 1997) cur-
rently provides the closest to population-based data on
the prevalence of the three common BRCA1 (MIM
113705) and BRCA2 (MIM 600185) founder mutations
in Ashkenazi Jewish women, so the most use must be
made of it. In this respect, Hartge et al. (1999) should
be congratulated for presenting raw data in their recent
publication in the Journal.
Hartge et al. (1999) use the classification-and-regres-
sion tree (CART) approach to identify the “most im-
portant” predictors of mutation status. They conclude
that a previous diagnosis of breast or ovarian cancer
was the most important discriminator. For women with
such a cancer history (i.e., affected individuals), the next
most important predictor was apparently age at diag-
nosis, after which “family history discriminated rela-
tively little” (p. 965). In contrast, for men and women
without a personal history of breast or ovarian cancer
(i.e., unaffected individuals), family history “best dis-
criminated” between carriers and noncarriers. In their
table 2, Hartge et al. present the most important sub-
categories of risk, derived by CART, along with the ob-
served frequency in each cell. The number of carriers in
some cells is small, however, making some inferences
imprecise.
The CART method for ranking predictors in terms of
“importance” is influenced by the distribution of pre-
dictive factors, not just by the size of the effect itself. It
is of interest, therefore, to estimate the strengths of pu-
tative predictive factors with regard to the probability
of being a carrier, both for affected and for unaffected
individuals. One way is by the use of multiple logistic
regression, in which the effects are estimated on the log-
odds scale. Not only does this statistical approach give
explicit estimates of the magnitude of the effects of pre-
dictors, along with measures of the precision of these
estimates (such as standard errors [SEs] and confidence
intervals [CIs]), it also allows one to summarize the data
in terms of as few parameters as is possible for extraction
of the most information. Such a “parsimonious” model
uses all the available information to produce a general
picture of the strength and nature of the major predictive
factors. (Hartge et al. [1999] do not report the findings
of logistic-regression analyses, apparently because they
found that the estimated frequencies were “substantially
higher” than the observed frequencies in groups with
observed prevalence 120%. As can be seen from their
tables 3 and 4, however, this only applied to 34 cases
at age !40 years at diagnosis, 20 of age 40–49 years at
diagnosis, and 10 of age 50–59 years at diagnosis, i.e.,
!2% of the 3,742 women in the total data set.)
Tables 1 and 2 present the observed prevalence of
mutation carriers, extracted from tables 3 and 4 of
Hartge et al. (1999), both for women with and for
women without a diagnosis of breast cancer, by age at
diagnosis or age at testing. It also categorizes women
according to their family history of breast or ovarian
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Table 2
Prevalence of the Three BRCA1 and BRCA2 Founder Mutations in Ashkenazi Jewish Women Who Have Had a Diagnosis of Breast Cancer,
as a Function of Family History of Breast Cancer (in a First-Degree Relative) and Age at Diagnosis (Hartge et al. [1999], table 4)
AGE AT DIAGNOSIS (YEARS)
PROPORTION (%) OF INDIVIDUALS WITH BRCA1/BRCA2 FOUNDER MUTATIONS WHEN
No. of First-Degree Relatives with Breast Cancer Is
Early Diagnosis in
Affected Relatives Is
0 1 2 Not Present Present
!40 6/27 (22) 3/7 (43) ) 1/3 (33) 2/4 (50)
40–49 6/77 (8) 3/25 (12) 2/7 (29) 2/23 (9) 3/9 (33)
50–59 2/59 (3) 3/21 (14) 1/2 (50) 2/15 (13) 2/8 (25)
60 1/47 (2) 0/22 (0) 0/3 (0) 0/15 (0) 0/10 (0)
Total 15/210 (7) 9/75 (12) 3/12 (25) 5/56 (9) 7/31 (23)
cancer, defined either by the number of first-degree rel-
atives with breast cancer or by whether any first-degree
relative had breast cancer diagnosed at age !50 years
(referred to there as “early diagnosis”). Several points
are readily seen:
1. The prevalence increases for each affected first-de-
gree relative, for both affected and unaffected individ-
uals; for example, as the number of affected relatives
increases from 0 to 1 to 2, the prevalence in affected
individuals increases from 1 in 14 to 1 in 8 to 1 in 4;
in unaffected individuals, it increases from 1 in 80 to 1
in 28 to 1 in 16.
2. In women with a family history, the prevalence is
greater if at least one of the affected relatives had an
early diagnosis, for both affected and unaffected
individuals.
3. There is a substantial difference, in prevalence be-
tween affected and unaffected individuals; this applies
to each of the family-history and age categories, al-
though it is not necessarily of the same strength in each
category.
4. There is evidence for an “age” effect in both affected
and unaffected individuals; for example, in wo-
men with a family history of breast cancer, the preva-
lence decreases from 43% to 16% to 8% as age at di-
agnosis increases from age !40 to 40–49 to 50 years.
In unaffected individuals, it decreases from 8% to 4%
to 2% as the age at testing increases from age 40 to
40–49 to 50 years.
Multiple logistic-regression analyses were conducted
for the data in tables 1 and 2, by use of the software
GLIM (Baker and Nelder 1978). Likelihood-ratio tests
were used to test between nested models, and the scaled
deviance was used as a goodness-of-fit test (McCullagh
and Nelder 1983).
First, family history was analyzed in terms of the num-
ber of affected first-degree relatives. (Note that there
were no women of age !40 years in the data set who
both were affected and had more than one affected first-
degree relative, so this category has been deleted from
the analysis.) In neither affected nor unaffected individ-
uals was there evidence for an interaction between the
effects of family history and “age” ( , ; and2x = 3.3 P = .65
, , respectively). Furthermore, the effects2x = 6.2 P = .46
of both age and family history were well represented by
one parameter each: a linear effect on the log-odds scale
per each age category (both , ) and per each2x ! 2 P ! .42
affected relative (both , ). Within each2x ! 0.1 P ! .81
group, there was no evidence that a logistic model that
involved such linear effects for age and number of af-
fected relatives gave an unacceptable fit ( ,2x = 7.5 P =9
; , , respectively). On the log-odds scale,2.6 x = 5.3 P = .78
the effect of age at diagnosis in affected individuals was
0.970 (SE, 0.257) per age category ( ), and theP ! .001
effect of age at testing in unaffected individuals was
0.434 (0.130) per age category ( ). The effectP ! .001
per affected relative was 0.826 (0.327) in affected in-
dividuals ( ) and 1.061 (0.222) in unaffected in-P = .01
dividuals ( ); that is, this family history effect wasP ! .001
no different between affected and unaffected individuals
( ).P = .6
When data from affected and unaffected individuals
were combined, the parsimonious model gave an ac-
ceptable fit ( ), and the linear predictor (with2x = 13.218
SEs of regression parameters in parentheses) was
( )0.986 0.185 # no. of affected relatives
( ) ( )[4.319 0.380 0.426 0.129
#age at testing in unaffecteds], or
( ) ( )[1.432 0.606 0.993 0.257
#age at diagnosis in affecteds] . (1)
(Here age is categorized as 1–4, respectively, for the
groups age !40, 40–49, 50–59, and 60 years.) The
effect of having one affected relative was 0.983 (0.232),
no different from that of having a second, which was
0.956 (0.503); . The average effect per affectedP 1 .9
relative was equivalent to the odds of being a mutation
carrier increasing by -fold (95% CI,exp (0.986) = 2.7
1.9–3.9) for each affected first-degree relative, irrespec-
Letters to the Editor 1773
tive of whether the woman was affected. In affected in-
dividuals, it decreased by 0.4-fold (95% CI, 0.2–0.6) per
category of age at diagnosis, whereas in unaffected in-
dividuals, it decreased by 0.7-fold (95% CI, 0.5–0.8) per
category of age at testing.
By a simple reparameterization, it can be shown that
the odds were greater in affected than in unaffected in-
dividuals with the same number of affected relatives, but
the difference depended on age at diagnosis/testing, de-
creasing from ∼10-fold (95% CI, 3.7–28), for women
of age !40 years, to 1.9-fold (95% CI, 1.4–2.4), for
women of age 60. The CIs indicate that the effect of
being affected was clearly significant at all ages.
Second, the same analysis was carried out again, this
time with women with a family history categorized as
0, for no relatives affected; 2, for having at least one
relative with “early diagnosis”; and 1 otherwise. As be-
fore, in neither affected nor unaffected individuals was
there evidence for an interaction between the effects of
family history of breast cancer and age ( ,2x = 3.3 P =6
; , , respectively). Furthermore, the effect2.6 x = 4.0 P = .76
of family history was well represented by a linear effect
on the log-odds scale, per each family-history category
(both , ), that was no different between2x ! 0.4 P = .82
affected and unaffected individuals; 0.752 (0.272) versus
0.741 (0.155), .P 1 .9
Combining affected and unaffected individuals, the
parsimonious model again gave an acceptable fit ( 2x =19
, ), and the linear predictor was10.7 P = .9
0.744 (0.135)# family history category
[4.184(0.371) 0.383(0.128)
#age at testing in unaffected individuals], or
[1.199(0.582) 0.862(0.251)
#age at diagnosis in affected individuals] ; (2)
that is, the estimated effects were very similar to those
in equation (1). (The effect of family history was 0.775
[0.287] in going from no family history to category 1,
no different from the effect of 0.705 [0.341] in going
from category 1 to category 2; .)P 1 .8
For both equation (1) and equation (2), there was no
evidence for a poor fit, in that the estimated probabilities
were not unduly disparate from the observed preva-
lences, in any category. In particular, for the two cate-
gories with the highest estimated probabilities according
to equation (1), .39 in both cases, the observed values
were .43 and .29 from samples of each. For equa-n = 7
tion (2), the three highest estimated probabilities were
.52, .34, and .29, similar to the observed prevalences of
.50, .33, and .33 from samples of , 3, and 9,n = 4
respectively.
The estimated probability of being a carrier, derived
from the parsimonious models (1) and (2) above, are
plotted, for the various categorizations in figure 1A–D.
It can be seen that, for women with the same family
history, the estimated probability in affected versus un-
affected individuals was approximately four times
greater for women in the youngest age category, but was
only approximately two times greater for those in the
oldest age category. That is, the effect of being affected
depended on “age,” a feature not discussed by Hartge
et al. (1999).
From figure 1A and B, it can be seen that the prob-
ability approximately doubled for each affected first-
degree relative. Figure 1C and D shows that, given a
family history, the probability approximately doubled
again if any of the affected relatives had an early di-
agnosis. These effects of family history were evi-
dent—and of the same magnitude on the log-odds
scale—in both affected and unaffected individuals, an-
other point not brought out by the CART analysis. We
cannot, however, on the basis of the published data, test
whether these effects were independent of one another.
In affected individuals, the probability approximately
halved for each decade of age at diagnosis, whereas in
unaffected individuals it approximately halved for every
2 decades of age at testing. The latter effect was not
apparent from the CART analysis.
Thus, our analyses of the published Washington data
suggest simple rules for how the probability that an Ash-
kenazi Jewish woman has inherited a founder mutation
in BRCA1 or BRCA2 depends on her personal or family
history of breast cancer. The effect of a having a single
first-degree relative with breast cancer is generally a
modest increase in prevalence equivalent to an odds ratio
of either 2.7 from equation (1) or 2.2 from equation (2),
both of which are similar to our estimate of 2.6 for a
defined set of protein-truncating mutations in BRCA1
and BRCA2 that cause breast cancer in Australian
women at age !40 years (Hopper et al. 1999). It would
be interesting to do a similar analysis for a family history
of ovarian cancer; table 1 of Hartge et al. (1999) sug-
gests that having at least one first-degree relative with
ovarian cancer is associated with an odds ratio of 4.1
(95% CI, 2.1–8.1) for having a founder mutation. Our
analysis above has shown that this effect was no different
from that of having a first-degree relative with breast
cancer ( ).P = .3
Hartge et al. (1999) note that their observed proba-
bilities for a given number of affected relatives were, in
general, less than those derived from data collected in
the setting of a cancer family clinic (Couch et al. 1997;
Shattuck-Eidens et al. 1997). The discrepancy is likely
to be due to the fact that the typical multiple-case fam-
ilies that come to such clinics also have cases with early-
onset disease and other features—such as multiple pri-
mary cancers or breast and ovarian cancer in the same
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Figure 1 Estimated probability of carrying a founder mutation in BRCA1 or BRCA2 for Ashkenazi women. A and C, women who have
had breast or ovarian cancer, as a function of age at diagnosis. B and D, women who have not had breast or ovarian cancer, as a function of
age at testing. In A and B, family history is defined in terms of number of first-degree relatives with breast cancer; in C and D, family history
is defined in terms of whether any first-degree relative had breast cancer at age !50 years (early diagnosis). (Note that because, in the data set,
there were no women age !40 years who were both affected and who had more than one affected first-degree relative, a probability has not
been assigned to that category.)
individual—that are also likely to increase their prob-
ability of being a carrier, as suggested by table 2 of
Hartge et al. (1999). Without knowledge of all these
predictors of mutation status it is not possible to make
a valid inference from the clinic setting to the population.
The majority of “hereditary” cases of breast and ovar-
ian cancer were “sporadic”; that is, 56% (15/27) of af-
fected women who carried a founder mutation had “no
breast cancer in [their] family” (see Hartge et al. 1999,
table 4). The same can be considered to have been ob-
served in Israel by Abeliovich et al. (1997), once atten-
tion is properly focused on their “unselected” sample of
just 24 carriers, of whom 58% (14) had no affected first-
degree relatives. This general observation also applies to
population-based samples of non-Ashkenazi popula-
tions. For example, in the United Kingdom, Peto et al.
(1999) found that of the 30 women who were diagnosed
with breast cancer at age45 years in whom a mutation
in BRCA1 or BRCA2 was detected, 57% (17) had no
family history of breast or ovarian cancer within three
generations. In Australia, we have found that 72% (13/
18) of BRCA1 or BRCA2 mutation-carrying cases di-
agnosed before age 40 years had no family history in
the preceding two generations (Hopper et al. 1999).
Furthermore, only a small proportion of the typical
women with “familial” breast cancer, defined as being
affected and as having a family history of breast cancer,
appear to have “hereditary” breast cancer, even in Ash-
kenazi Jews, in whom 12% of the population carries a
mutation associated with a not-inconsiderable lifetime
risk of ∼50% (Struewing et al. 1997). The Washington
study, in which there was a small bias toward living
subjects having an excess of family history of breast
cancer (Struewing et al. 1997), found that !10% of fa-
milial cases carried a founder mutation (Hartge et al.
1999), although it is conceivable that a smaller propor-
tion may carry another “high-risk” mutation, either in
BRCA1 or BRCA2 or, perhaps, another such gene whose
normal function is to protect women from breast cancer.
In our Australian population-based study of women
with breast cancer at age !40 years, we detected a pro-
tein-truncating mutation in only 5% (6/120) of cases
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with at least one affected first- or second-degree relative
and in 9% (5/53) of cases with an affected first-degree
relative, in a mutation screen covering between two-
thirds and three-quarters of the coding regions of these
two genes (Hopper et al. 1999, table 3).
Finally, the strong and highly significant effect that
having had breast cancer has on the probability of being
a mutation carrier could be used to derive an estimate
of penetrance (i.e., age-specific cumulative risk of breast
cancer), by using a case-control argument and appro-
priate population incidence rates and by taking into ac-
count the strong dependence of this effect on age, in
which the odds ratio decreases from 10- to 2-fold across
the four categories. In this regard, it is of interest that
we found an average odds ratio of 9-fold for a set of
protein-truncating mutations in BRCA1 and BRCA2
that cause early-onset breast cancer—and that this trans-
lates into a penetrance, until age 70 years, of just 40%
when applied to Australian population rates (Hopper
et al. 1999). Therefore, it is likely that a similar lifetime-
penetrance estimate would apply to the founder mu-
tations among U.S. Ashkenazi women, once the dimin-
ishing effect with age observed here has been counter-
balanced by the ∼30% higher underlying rates in the
United States compared with Australia. Thus, popula-
tion-based data on mutation carriers, such as those pro-
vided in some detail by Hartge and colleagues, are pro-
viding a new perspective on how genetic factors are
evident in common diseases, challenging previous beliefs
and language based on “monogenic” diseases (see Hop-
per et al. 1999).
JOHN L. HOPPER AND MARK A. JENKINS
Centre for Genetic Epidemiology, The University
of Melbourne, Carlton, Victoria, Australia
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